Article

More patients may be candidates for multifocal IOLs than anticipated

Cataract surgery patients with a healthy eye suitable for a multifocal IOL should be offered that option in preoperative counseling, said Kenneth J. Rosenthal, MD, a private practitioner in Great Neck, NY.

Cataract surgery patients with a healthy eye suitable for a multifocal IOL should be offered that option in preoperative counseling, said Kenneth J. Rosenthal, MD, a private practitioner in Great Neck, NY.

Dr. Rosenthal said that when it comes to deciding who are good candidates for a multifocal implant, he differs from conventional "wisdom," which primarily considers lifestyle factors and patient motivation for spectacle independence.

"Most patients cannot intuit how fantastic it is to be spectacle-independent after cataract surgery, and our experience has been that every patient who receives a multifocal IOL is ecstatic beyond what they anticipated, even if they were indifferent before surgery," Dr. Rosenthal said.

Thorough counseling about all pseudophakic IOL options and extensive evaluation to identify any subtle problems that may affect outcomes involves a significant time commitment. Ultimately, it is the patient's decision on which implant to receive.

For those who select the multifocal implant, a successful outcome also involves comprehensive preoperative diagnostic testing, meticulous surgical technique, and postoperative counseling that focuses on enhancing adaptation.

"There is tremendous variation in how quickly multifocal IOL patients adapt, but we tell them it can take several months and up to 1 year," Dr. Rosenthal said. "However, nonadapters are rare if we follow the strategies outlined for achieving success after multifocal IOL implantation."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.